Terms: = Leukemia AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
511 results:
1. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract] [Full Text] [Related]
2. Novel guanidine derivatives targeting leukemia as selective Src/Abl dual inhibitors: Design, synthesis and anti-proliferative activity.
Moustafa AH; AboulMagd AM; Ali AM; Khodairy A; Marzouk AA; Nafady A; T M Nemr M
Bioorg Chem; 2024 Jun; 147():107410. PubMed ID: 38688197
[TBL] [Abstract] [Full Text] [Related]
3. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S; Mutlu YG; Malkan ÜY; Mehtap Ö; Keklik Karadağ F; Korkmaz G; Elverdi T; Saydam G; Özet G; Ar MC; Melek E; Maral S; Kaynar L; Sevindik ÖG
Leuk Res; 2024 May; 140():107495. PubMed ID: 38599153
[TBL] [Abstract] [Full Text] [Related]
4. Splenic B-cell lymphoma/leukemia with prominent nucleoli: A three-case series of the newly named old entity and review of literature.
Rai V; Saha A; Gondha S; Manimaran P; Sawhney J
J Cancer Res Ther; 2024 Jan; 20(1):315-320. PubMed ID: 38554340
[TBL] [Abstract] [Full Text] [Related]
5. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
6. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
7. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
8. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
9. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.
Chang L; Lang M; Lin H; Cai H; Duan MH; Zhou DB; Cao XX
Leukemia; 2024 Apr; 38(4):803-809. PubMed ID: 38388646
[TBL] [Abstract] [Full Text] [Related]
10. Clinical and molecular study of radiation-induced gliomas.
Trkova K; Sumerauer D; Bubenikova A; Krskova L; Vicha A; Koblizek M; Zamecnik J; Jurasek B; Kyncl M; Malinova B; Ondrova B; Jones DTW; Sill M; Strnadova M; Stolova L; Misove A; Benes V; Zapotocky M
Sci Rep; 2024 Feb; 14(1):3118. PubMed ID: 38326438
[TBL] [Abstract] [Full Text] [Related]
11. New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell leukemia.
Soong D; Taylor J
NEJM Evid; 2023 Oct; 2(10):EVIDe2300173. PubMed ID: 38320184
[TBL] [Abstract] [Full Text] [Related]
12. Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies.
Youssif BGM; Morcoss MM; Bräse S; Abdel-Aziz M; Abdel-Rahman HM; Abou El-Ella DA; Abdelhafez ESMN
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257358
[TBL] [Abstract] [Full Text] [Related]
13. Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Zhou Q; Zhang J; Zhang J; Liang S; Cai D; Xiao H; Zhu Y; Xiang W; Rodrigues-Lima F; Chi J; Guidez F; Wang L
Biol Direct; 2024 Jan; 19(1):6. PubMed ID: 38178263
[TBL] [Abstract] [Full Text] [Related]
14. Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.
Ferenczi K; Nagy ZF; Istenes I; Eid H; Bödör C; Timár B; Demeter J
Pathol Oncol Res; 2023; 29():1611378. PubMed ID: 38025907
[No Abstract] [Full Text] [Related]
15. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
16. Exploration of antiproliferative potential of modified triazole-benzohydrazone scaffold: Multitarget approach.
Ali AM; Khalaf MA; Bhongade BA; Selim KB; Mostafa AS
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300383. PubMed ID: 37946599
[TBL] [Abstract] [Full Text] [Related]
17. Long term activity of vemurafenib in cancers with braf mutations: the ACSE basket study for advanced cancers other than braf
Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
[TBL] [Abstract] [Full Text] [Related]
18. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
19. Impact of
Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
[TBL] [Abstract] [Full Text] [Related]
20. KZ02 enhances the radiosensitivity of braf-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
[Next]
